Lipid-Lowering Agents - Nordics

Nordics

The Lipid-Lowering Agents market in the Nordics is forecasted to achieve a revenue of US$70.16m in 2024.
It is expected to exhibit a compound annual growth rate (CAGR 2024-2029) of -0.32%, leading to a market volume of US$69.04m by 2029.
Comparatively, United States is projected to generate the highest revenue of US$4,461.00m in 2024, on a global scale.
In the Nordics, there is a growing demand for lipid-lowering agents as a result of increasing awareness about cardiovascular health.

Key regions: Europe, Brazil, France, Australia, Germany

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for Lipid-Lowering Agents in the Nordics has been on the rise in recent years.

Customer preferences: The market for Lipid-Lowering Agents in the Nordics is driven by a growing awareness among consumers about the health risks associated with high cholesterol levels. Consumers are increasingly seeking out products that can help them manage their cholesterol levels and reduce the risk of heart disease.

Trends in the market: One of the key trends in the Lipid-Lowering Agents market in the Nordics is the growing popularity of natural and plant-based products. Consumers are increasingly looking for products that are made from natural ingredients and do not contain harmful chemicals or additives. This trend is driving the growth of natural and plant-based Lipid-Lowering Agents in the region.Another trend in the market is the increasing availability of Lipid-Lowering Agents over-the-counter. This has made it easier for consumers to access these products and has contributed to the growth of the market in the region.

Local special circumstances: The Nordic region has a high incidence of heart disease and other cardiovascular conditions. This has created a strong demand for Lipid-Lowering Agents in the region, as consumers look for ways to manage their cholesterol levels and reduce their risk of heart disease.

Underlying macroeconomic factors: The growing demand for Lipid-Lowering Agents in the Nordics is being driven by a number of underlying macroeconomic factors. These include an aging population, rising healthcare costs, and increasing awareness about the health risks associated with high cholesterol levels. These factors are expected to continue to drive growth in the Lipid-Lowering Agents market in the region in the coming years.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.